134 related articles for article (PubMed ID: 3026973)
1. Expression of B-cell-specific markers in different Burkitt lymphoma subgroups.
Ehlin-Henriksson B; Manneborg-Sandlund A; Klein G
Int J Cancer; 1987 Feb; 39(2):211-8. PubMed ID: 3026973
[TBL] [Abstract][Full Text] [Related]
2. Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Ehlin-Henriksson B; Klein G
Int J Cancer; 1984 Apr; 33(4):459-63. PubMed ID: 6231253
[TBL] [Abstract][Full Text] [Related]
3. Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus.
Gregory CD; Edwards CF; Milner A; Wiels J; Lipinski M; Rowe M; Tursz T; Rickinson AB
Int J Cancer; 1988 Aug; 42(2):213-20. PubMed ID: 2841246
[TBL] [Abstract][Full Text] [Related]
4. EBV-negative and -positive Burkitt cell lines variably express receptors for B-cell activation and differentiation.
Favrot MC; Maritaz O; Suzuki T; Cooper M; Philip I; Philip T; Lenoir G
Int J Cancer; 1986 Dec; 38(6):901-6. PubMed ID: 3025106
[TBL] [Abstract][Full Text] [Related]
5. Expression of the BLA antigen, defined by the monoclonal 38.13 antibody, on Burkitt lymphoma lines, lymphoblastoid cell lines, their hybrids and other B-cell lymphomas and leukemias.
Klein G; Manneborg-Sandlund A; Ehlin-Henriksson B; Godal T; Wiels J; Tursz T
Int J Cancer; 1983 May; 31(5):535-42. PubMed ID: 6303966
[TBL] [Abstract][Full Text] [Related]
6. A monoclonal antibody with anti-Burkitt lymphoma specificity. I. Analysis of human haematopoietic and lymphoid cell lines.
Wiels J; Lenoir GM; Fellous M; Lipinski M; Salomon JC; Tetaud C; Tursz T
Int J Cancer; 1982 Jun; 29(6):653-8. PubMed ID: 6286514
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
Masucci MG; Torsteindottir S; Colombani J; Brautbar C; Klein E; Klein G
Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4567-71. PubMed ID: 3037521
[TBL] [Abstract][Full Text] [Related]
8. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains.
Klein G; Ehlin-Henriksson B; Schlossman SF
J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235
[TBL] [Abstract][Full Text] [Related]
9. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype.
Gregory CD; Tursz T; Edwards CF; Tetaud C; Talbot M; Caillou B; Rickinson AB; Lipinski M
J Immunol; 1987 Jul; 139(1):313-8. PubMed ID: 2953817
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment with interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha up-regulates the expression of HLA class I determinants in Burkitt lymphoma lines.
Avila-Carino J; Torsteinsdottir S; Bejarano MT; Klein G; Klein E; Masucci MG
Cell Immunol; 1988 Dec; 117(2):303-11. PubMed ID: 2848629
[TBL] [Abstract][Full Text] [Related]
11. Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype.
Falk MH; Trauth BC; Debatin KM; Klas C; Gregory CD; Rickinson AB; Calender A; Lenoir GM; Ellwart JW; Krammer PH
Blood; 1992 Jun; 79(12):3300-6. PubMed ID: 1375849
[TBL] [Abstract][Full Text] [Related]
12. Subgroup analysis of BL-cell lines with polyclonal BL-specific antibodies.
Gazitt Y; Ehlin-Henriksson B; Lerner A; Klein G
Int J Cancer; 1984 Dec; 34(6):839-43. PubMed ID: 6439652
[TBL] [Abstract][Full Text] [Related]
13. Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines.
Rooney CM; Gregory CD; Rowe M; Finerty S; Edwards C; Rupani H; Rickinson AB
J Natl Cancer Inst; 1986 Sep; 77(3):681-7. PubMed ID: 2943927
[TBL] [Abstract][Full Text] [Related]
14. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
[TBL] [Abstract][Full Text] [Related]
15. SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation.
Nagy N; Maeda A; Bandobashi K; Kis LL; Nishikawa J; Trivedi P; Faggioni A; Klein G; Klein E
Int J Cancer; 2002 Aug; 100(4):433-40. PubMed ID: 12115526
[TBL] [Abstract][Full Text] [Related]
16. EBNA promoter usage in EBV-negative Burkitt lymphoma cell lines converted with a neomycin-resistant EBV strain.
Maeda A; Kiss C; Chen F; Ehlin-Henriksson B; Nagy N; Szekely L; Takada K; Klein E; Klein G
Int J Cancer; 2001 Sep; 93(5):714-9. PubMed ID: 11477584
[TBL] [Abstract][Full Text] [Related]
17. Expression of interleukin 10 in B lymphocytes of different origin.
Finke J; Ternes P; Lange W; Mertelsmann R; Dölken G
Leukemia; 1993 Nov; 7(11):1852-7. PubMed ID: 7694007
[TBL] [Abstract][Full Text] [Related]
18. Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines.
Pokrovskaja K; Ehlin-Henriksson B; Bartkova J; Bartek J; Scuderi R; Szekely L; Wiman KG; Klein G
Cell Growth Differ; 1996 Dec; 7(12):1723-32. PubMed ID: 8959341
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of a new human Burkitt's lymphoma cell line (WSU-BL).
Mohamed AN; Mohammad RM; Koop BF; al-Katib A
Cancer; 1989 Sep; 64(5):1041-8. PubMed ID: 2527086
[TBL] [Abstract][Full Text] [Related]
20. Induction of cell differentiation in Burkitt lymphoma lines. BLA: a glycolipid marker of B-cell differentiation.
Balana A; Wiels J; Tetaud C; Mishal Z; Tursz T
Int J Cancer; 1985 Oct; 36(4):453-60. PubMed ID: 3930411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
